First-ever treatment in multiple sclerosis

•Both fingolimod and dimethyl fumarate reduce significantly the risk of disease progression in early-treated treatment-naive patients.•There seems to be a prescription bias towards fingolimod in more active patients.•Highly active patients at baseline are at higher risk of disease progression. The c...

Full description

Saved in:
Bibliographic Details
Published in:Revue neurologique 2021-01, Vol.177 (1-2), p.93-99
Main Authors: Pantazou, V., Pot, C., Du Pasquier, R., Le Goff, G., Théaudin, M.
Format: Article
Language:English
Subjects:
Dimethyl fumarate
Disease modifying treatment
Fingolimod
Multiple sclerosis
Real-world study
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c357t-6c86a0fccaab61f15b134b10391e5d57bfa91d58d2a8766688e1f66545b632643
container_end_page 99
container_issue 1-2
container_start_page 93
container_title Revue neurologique
container_volume 177
creator Pantazou, V.
Pot, C.
Du Pasquier, R.
Le Goff, G.
Théaudin, M.
description •Both fingolimod and dimethyl fumarate reduce significantly the risk of disease progression in early-treated treatment-naive patients.•There seems to be a prescription bias towards fingolimod in more active patients.•Highly active patients at baseline are at higher risk of disease progression. The current treated MS population is very different from that of patients in randomized clinical trials. To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration>12months. Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P
doi_str_mv 10.1016/j.neurol.2020.05.014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2432432938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0035378720306263</els_id><sourcerecordid>2432432938</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-6c86a0fccaab61f15b134b10391e5d57bfa91d58d2a8766688e1f66545b632643</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhnNQ3HX1H4j0KELrJGmS9iLI4qqw4EXPIU2nkKUfa5Iu-O_t0tWjMDCX552Ph5AbChkFKh92WY-jH9qMAYMMRAY0PyNLAC5Srgq1IJch7AAYVcAvyIIzpSiDcknuN86HmOIBfRI9mthhHxPXJ93YRrdvMQm2RT8EF67IeWPagNenviKfm-eP9Wu6fX95Wz9tU8uFiqm0hTTQWGtMJWlDRUV5XlHgJUVRC1U1pqS1KGpmCiWlLAqkjZQiF5XkTOZ8Re7muXs_fI0You5csNi2psdhDJrl_FglLyY0n1E7XRg8NnrvXWf8t6agj2b0Ts9m9NGMBqEnM1Ps9rRhrDqs_0K_WibgcQZw-vPg0OtgHfYWa-fRRl0P7v8NPxpwd1s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432432938</pqid></control><display><type>article</type><title>First-ever treatment in multiple sclerosis</title><source>ScienceDirect Journals</source><creator>Pantazou, V. ; Pot, C. ; Du Pasquier, R. ; Le Goff, G. ; Théaudin, M.</creator><creatorcontrib>Pantazou, V. ; Pot, C. ; Du Pasquier, R. ; Le Goff, G. ; Théaudin, M.</creatorcontrib><description>•Both fingolimod and dimethyl fumarate reduce significantly the risk of disease progression in early-treated treatment-naive patients.•There seems to be a prescription bias towards fingolimod in more active patients.•Highly active patients at baseline are at higher risk of disease progression. The current treated MS population is very different from that of patients in randomized clinical trials. To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration&gt;12months. Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P&lt;0.001). The main reason for discontinuation was disease activity without severe side effects on either treatment. Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.</description><identifier>ISSN: 0035-3787</identifier><identifier>DOI: 10.1016/j.neurol.2020.05.014</identifier><identifier>PMID: 32771209</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Dimethyl fumarate ; Disease modifying treatment ; Fingolimod ; Multiple sclerosis ; Real-world study</subject><ispartof>Revue neurologique, 2021-01, Vol.177 (1-2), p.93-99</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-6c86a0fccaab61f15b134b10391e5d57bfa91d58d2a8766688e1f66545b632643</cites><orcidid>0000-0002-3026-3595</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32771209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pantazou, V.</creatorcontrib><creatorcontrib>Pot, C.</creatorcontrib><creatorcontrib>Du Pasquier, R.</creatorcontrib><creatorcontrib>Le Goff, G.</creatorcontrib><creatorcontrib>Théaudin, M.</creatorcontrib><title>First-ever treatment in multiple sclerosis</title><title>Revue neurologique</title><addtitle>Rev Neurol (Paris)</addtitle><description>•Both fingolimod and dimethyl fumarate reduce significantly the risk of disease progression in early-treated treatment-naive patients.•There seems to be a prescription bias towards fingolimod in more active patients.•Highly active patients at baseline are at higher risk of disease progression. The current treated MS population is very different from that of patients in randomized clinical trials. To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration&gt;12months. Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P&lt;0.001). The main reason for discontinuation was disease activity without severe side effects on either treatment. Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.</description><subject>Dimethyl fumarate</subject><subject>Disease modifying treatment</subject><subject>Fingolimod</subject><subject>Multiple sclerosis</subject><subject>Real-world study</subject><issn>0035-3787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhnNQ3HX1H4j0KELrJGmS9iLI4qqw4EXPIU2nkKUfa5Iu-O_t0tWjMDCX552Ph5AbChkFKh92WY-jH9qMAYMMRAY0PyNLAC5Srgq1IJch7AAYVcAvyIIzpSiDcknuN86HmOIBfRI9mthhHxPXJ93YRrdvMQm2RT8EF67IeWPagNenviKfm-eP9Wu6fX95Wz9tU8uFiqm0hTTQWGtMJWlDRUV5XlHgJUVRC1U1pqS1KGpmCiWlLAqkjZQiF5XkTOZ8Re7muXs_fI0You5csNi2psdhDJrl_FglLyY0n1E7XRg8NnrvXWf8t6agj2b0Ts9m9NGMBqEnM1Ps9rRhrDqs_0K_WibgcQZw-vPg0OtgHfYWa-fRRl0P7v8NPxpwd1s</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Pantazou, V.</creator><creator>Pot, C.</creator><creator>Du Pasquier, R.</creator><creator>Le Goff, G.</creator><creator>Théaudin, M.</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3026-3595</orcidid></search><sort><creationdate>202101</creationdate><title>First-ever treatment in multiple sclerosis</title><author>Pantazou, V. ; Pot, C. ; Du Pasquier, R. ; Le Goff, G. ; Théaudin, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-6c86a0fccaab61f15b134b10391e5d57bfa91d58d2a8766688e1f66545b632643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Dimethyl fumarate</topic><topic>Disease modifying treatment</topic><topic>Fingolimod</topic><topic>Multiple sclerosis</topic><topic>Real-world study</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pantazou, V.</creatorcontrib><creatorcontrib>Pot, C.</creatorcontrib><creatorcontrib>Du Pasquier, R.</creatorcontrib><creatorcontrib>Le Goff, G.</creatorcontrib><creatorcontrib>Théaudin, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revue neurologique</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pantazou, V.</au><au>Pot, C.</au><au>Du Pasquier, R.</au><au>Le Goff, G.</au><au>Théaudin, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-ever treatment in multiple sclerosis</atitle><jtitle>Revue neurologique</jtitle><addtitle>Rev Neurol (Paris)</addtitle><date>2021-01</date><risdate>2021</risdate><volume>177</volume><issue>1-2</issue><spage>93</spage><epage>99</epage><pages>93-99</pages><issn>0035-3787</issn><abstract>•Both fingolimod and dimethyl fumarate reduce significantly the risk of disease progression in early-treated treatment-naive patients.•There seems to be a prescription bias towards fingolimod in more active patients.•Highly active patients at baseline are at higher risk of disease progression. The current treated MS population is very different from that of patients in randomized clinical trials. To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment duration&gt;12months. Demographics and MRI characteristics at baseline were similar in both groups (FTY 55 patients, DMF 20), but patients on FTY had higher pretreatment clinical activity (P=0.008). Twenty-two percent of patients in the FTY group and 15% in the DMF group had highly active disease. At last follow-up (mean: 44.2, SD: 17.3months), the majority of the patients were still on treatment while 54.5% of FTY and 65% of DMF patients reached NEDA 3 status (P=0.444). Both treatments significantly decreased relapses and occurrence of new T1 Gd-enhancing lesions (P&lt;0.001). The main reason for discontinuation was disease activity without severe side effects on either treatment. Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>32771209</pmid><doi>10.1016/j.neurol.2020.05.014</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3026-3595</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0035-3787
ispartof Revue neurologique, 2021-01, Vol.177 (1-2), p.93-99
issn 0035-3787
language eng
recordid cdi_proquest_miscellaneous_2432432938
source ScienceDirect Journals
subjects Dimethyl fumarate
Disease modifying treatment
Fingolimod
Multiple sclerosis
Real-world study
title First-ever treatment in multiple sclerosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A17%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-ever%20treatment%20in%20multiple%20sclerosis&rft.jtitle=Revue%20neurologique&rft.au=Pantazou,%20V.&rft.date=2021-01&rft.volume=177&rft.issue=1-2&rft.spage=93&rft.epage=99&rft.pages=93-99&rft.issn=0035-3787&rft_id=info:doi/10.1016/j.neurol.2020.05.014&rft_dat=%3Cproquest_cross%3E2432432938%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357t-6c86a0fccaab61f15b134b10391e5d57bfa91d58d2a8766688e1f66545b632643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2432432938&rft_id=info:pmid/32771209&rfr_iscdi=true